Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Plus Therapeutics, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 11 months agoplustherapeutics.com
Plus Therapeutics, Inc., often referred to simply as Plus Therapeutics, is a leading US-based pharmaceutical company focused on innovative oncology treatments. Established in 2008, the company is a key player in the Pharmaceutical Preparation Manufacturing industry, dedicated to developing novel therapies for difficult-to-treat cancers.
Headquartered in Austin, Texas, Plus Therapeutics specialises in targeted radiotherapeutics. Their lead product candidate, Rhenium-186 NanoLiposome (186RNL), exemplifies their pioneering approach, offering a unique radiation therapy for recurrent glioblastoma and leptomeningeal metastases, addressing significant unmet medical needs. Through their advanced research and development, Plus Therapeutics strives to improve patient outcomes and reshape the landscape of cancer care.
23
DitchCarbon score
-19 vs industry average
Plus Therapeutics, Inc.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Plus Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Plus Therapeutics, Inc. yet.
Plus Therapeutics, Inc.'s reported carbon emissions
Plus Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any specific reduction targets or initiatives related to climate commitments. Without emissions data or defined climate strategies, it is challenging to assess their environmental impact or commitments within the industry context. As such, Plus Therapeutics appears to be in the early stages of developing a comprehensive approach to carbon management and sustainability.
Assessing Plus Therapeutics, Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Plus Therapeutics, Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Plus Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Plus Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Plus Therapeutics, Inc.11 months ago
23
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more